944718-10-9

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMOMETHYL-6-METHOXYISOINDOLINONE is used as an intermediate in the synthesis of pharmaceuticals for its potential pharmacological properties. It has been studied for its anti-inflammatory and analgesic effects, making it a promising candidate for the development of new medications.
Used in Chemical Research:
In the field of chemical research, 2-BROMOMETHYL-6-METHOXYISOINDOLINONE is utilized as a building block for the synthesis of various heterocyclic compounds. Its unique structure allows for the creation of a wide range of organic compounds, contributing to the advancement of chemical science.

InChI:InChI=1/C10H10BrNO2/c1-14-8-3-2-7-5-12(6-11)10(13)9(7)4-8/h2-4H,5-6H2,1H3

Upstream product

• 944718-09-6 2,2-Dimethyl-propionic acid 6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl ester 
• 73502-03-1 methyl 5-methoxy-2-methyl-benzoate 
• 788081-99-2 methyl 2-(bromomethyl)-5-methoxy-benzoate 
• 22246-66-8 6-methoxy-2,3-dihydro-isoindol-1-one 
• 35450-36-3 methyl 2-bromo-5-methoxybenzoate 

Downstream Products

• 944718-26-7 (R)-2-Methoxycarbonylamino-2-(6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4-(4-sulfo-phenyl)-but-3-ynoic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of [3H], [13C3, 15N], and [14C]SCH 900567: An inhibitor of TNF-α (tumor necrosis factor alpha) converting enzyme (TACE)

SCH 900567 is a specific inhibitor of tumor necrosis factor-alpha converting enzyme and is a potential candidate for the treatment of rheumatoid arthritis. [3H]SCH 900567 was synthesized to support the initial drug metabolism and pharmacokinetics studies. Stable isotope-labeled [13C3, 15N]SCH 900567 was requested by the bioanalytical group as an internal standard for Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method development as well as by the drug metabolism and pharmacokinetics group for a potential microdose study. [13C3, 15N]SCH 900567 is synthesized via a linear sequence of seven steps from commercially available materials in 2.6% overall yield. [14C]SCH 900567 was needed for a quantitative whole body autoradiography studies and was prepared from unlabeled Active Pharmaceutical Ingredient (API) via hydrolysis of the hydantoin moiety followed by rebuilding the hydantoin ring using potassium [14C]cyanate to give the desired product in 42.8% overall yield. Activation of the hydantoin moiety of SCH 900567 to achieve hydrolysis followed by derivatization of the resulting amino acid to avoid decarboxylation during cyclization is also discussed.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, T

Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases

Our research on hydantoin based TNF-α converting enzyme (TACE) inhibitors has led to an acetylene containing series that demonstrates sub-nanomolar potency (Ki) as well as excellent activity in human whole blood. These studies led to the discov

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula: (I); or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α or combinations thereof.